Evidence map›Paper›PMID 26384299›Full record

SynthesisOncotarget2015

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.

Claudio Luchini, Nicola Veronese, Marco Solmi, Hanbyoul Cho, Jae-Hoon Kim, Angela Chou, Anthony J Gill, Sheila F Faraj, Alcides Chaux, George J Netto and 22 more

Open access · diamondAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2016
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Therapeutic Role of Synthetic Lethality inJournal of immunotherapy and precision oncology · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Relevance ofDiagnostics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 17 institutions in 9 countries.

Claudio LuchiniDepartment of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
Nicola VeroneseDepartment of Medicine, Geriatrics Division, University of Padova, Padova, Italy.
Marco SolmiDepartment of Neurosciences, University of Padova, Padova, Italy.
Hanbyoul ChoDepartment of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Jae-Hoon KimDepartment of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Angela ChouCancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St. Leonards, Australia.
Anthony J GillCancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St. Leonards, Australia.
Sheila F FarajDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Alcides ChauxDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
George J NettoDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Kentaro NakayamaDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Shimane, Japan.
Satoru KyoDepartment of Obstetrics and Gynecology, Shimane University School of Medicine, Shimane, Japan.
Soo Young LeeLee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, South Korea.
Duck-Woo KimDepartment of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
George M YousefDepartment of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
Andreas ScorilasDepartment of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Athens, Greece.
Gregg S NelsonDepartment of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Steve E KallogerDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
David F SchaefferDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Hai-Bo YanDepartment of Systems Biology for Medicine of School of Basic Medical Sciences, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Feng LiuDepartment of Systems Biology for Medicine of School of Basic Medical Sciences, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Yoshihito YokoyamaDepartment of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Xianyu ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Da PangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Zsuzsanna LichnerDepartment of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
Giuseppe SergiDepartment of Medicine, Geriatrics Division, University of Padova, Padova, Italy.
Enzo ManzatoDepartment of Medicine, Geriatrics Division, University of Padova, Padova, Italy.
Paola CapelliDepartment of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
Laura D WoodDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Aldo ScarpaDepartment of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
Christoph U CorrellThe Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island Jewish Health System, Glen Oaks, New York, USA.
Johns Hopkins University · USUniversity of Padua · ITFudan University · CNSt. Michael's Hospital · CAThe University of Sydney · AUThird Affiliated Hospital of Harbin Medical University · CNUniversity of British Columbia · CAYonsei University · KRAlbert Einstein College of Medicine · USGachon University · KRHirosaki University · JPNational and Kapodistrian University of Athens · GRParaguayan Center for Population Studies · PYSeoul National University Bundang Hospital · KRShimane University · JPUniversity of Calgary · CAUniversity of Shimane · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of the tumor suppressor gene AT-rich interactive domain-containing protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic role is unknown. We aimed to investigate the risk associated with loss of ARID1A (ARID1A-) for all-cause mortality, cancer-specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS search from database inception until 01/31/2015 without language restriction was conducted, contacting authors for unpublished data. Eligible were prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of ARID1A (ARID1A+) vs. ARID1A-, assessed either via immunohistochemistry (loss of expression) or with genetic testing (presence of mutation). Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time-dependent risk related to ARID1A- adjusted for potential confounders. Of 136 hits, 25 studies with 5,651 participants (28 cohorts; ARID1A-: n = 1,701; ARID1A+: n = 3,950), with a mean follow-up period of 4.7 ± 1.8 years, were meta-analyzed. Compared to ARID1A+, ARID1A- significantly increased cancer-specific mortality (studies = 3; RR = 1.55, 95% confidence interval (CI) = 1.19-2.00, I(2) = 31%). Using HRs adjusted for potential confounders, ARID1A- was associated with a greater risk of cancer-specific mortality (studies = 2; HR = 2.55, 95%CI = 1.19-5.45, I(2) = 19%) and cancer recurrence (studies = 10; HR = 1.93, 95%CI = 1.22-3.05, I(2) = 76%). On the basis of these results, we have demonstrated that loss of ARID1A shortened time to cancer-specific mortality, and to recurrence of cancer when adjusting for potential confounders. For its role, this gene should be considered as an important potential target for personalized medicine in cancer treatment.

Indexed as

Genes, Tumor SuppressorCohort StudiesDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMutationNeoplasmsNuclear ProteinsPrognosisTranscription FactorsARID1A protein, humanDNA-Binding ProteinsNuclear ProteinsTranscription FactorsARID1Achromatin remodelingSWI/SNFtargeted therapytumor suppressor gene

Identifiers

PMID26384299
PMCPMC4770758
OpenAlexW2140087277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.